Compare PROP & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | NSRX |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 37.1M |
| IPO Year | 2008 | 2024 |
| Metric | PROP | NSRX |
|---|---|---|
| Price | $0.31 | $2.60 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.50 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 1.2M | 13.6K |
| Earning Date | 11-12-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 49.06 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,939,000.00 | N/A |
| Revenue This Year | $85.81 | N/A |
| Revenue Next Year | $11.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 413.59 | N/A |
| 52 Week Low | $0.30 | $1.98 |
| 52 Week High | $2.55 | $9.50 |
| Indicator | PROP | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.77 | 35.60 |
| Support Level | N/A | $2.41 |
| Resistance Level | $0.44 | $3.61 |
| Average True Range (ATR) | 0.05 | 0.20 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 2.94 | 21.47 |
Prairie Operating Co is an independent oil and natural gas company focused on the acquisition and development of crude oil, natural gas, and natural gas liquids (NGLs). Its assets and operations are located in the oil region of rural Weld County, Colorado, within the Denver-Julesburg Basin in Colorado (the DJ Basin). The company generates maximum revenue from crude oil sales, and the rest from the sale of natural gas and natural gas liquids.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.